Teva Pharmaceuticals USA, Inc., a U.S. affiliate of Teva Pharmaceutical Industries Ltd. announced the launch of its 1000 mg strength generic version of Casana®1 (mesalamine) suppository medicine used to treat adults with active ulcerative proctitis (ulcerative rectal colitis), in the U.S.
Mesalamine suppositories have annual sales of more than $74 million in the U.S., according to IQVIA data as of February 2021.
1 CANASA and its design are trademarks of Aptalis Pharma Canada ULC, an AbbVie company.
